G1 Therapeutics, Inc. is a privately held pharmaceutical company based in Chapel Hill, NC that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications. These molecules are being developed for targeting specific proteins associated with cell proliferation and growth. Such therapies may be useful to protect the bone marrow and other organs, including the kidney and lung, from toxic insult.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/16/13 | $12,500,000 | Series A |
Hatteras Venture Partners Mountain Group Capital | undisclosed |
| 05/12/16 | $47,000,000 | Series C |
AJU IB Investment Cormorant Asset Management Cowen Private Investments Eshelman Ventures Franklin Templeton Hatteras Venture Partners Lumira Capital Mountain Group Capital RA Capital Rock Springs Capital | undisclosed |
